GAO Rejects Rubber-Stamp LPTA Technical Evaluation
Client Alert | less than 1 min read | 12.14.15
In a low-price-technically-acceptable procurement for IDIQ contracts for flame-resistant Army combat shirts, GAO sustained a challenge to the technical evaluation because the agency did not critically evaluate whether any of the three awardees' proposals actually met a particular solicitation requirement. GAO rejected the agency's nondescript finding that each awardee's proposal was "acceptable," and instead concluded that none of the awardees had provided a meaningful narrative addressing the requirement and that one, in fact, had included test data in its proposal showing that it did not meet the requirement.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
